REFERENCES
- Hanahan D, Weinberg R A. The hallmarks of cancer. Cell 2000; 100: 57–70, [INFOTRIEVE], [CSA]
- Woodhouse E C, Chuaqui R F, Liotta L A. General mechanisms of metastasis. Cancer 1997; 80: 1529–1537, [INFOTRIEVE], [CSA], [CROSSREF]
- Geho D H, Bandle R W, Clair T, Liotta L A. Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) 2005; 20: 194–200, [CSA]
- Littlepage L E, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005; 7: 499–500, [INFOTRIEVE], [CSA], [CROSSREF]
- Ronnov-Jessen L, Petersen O W, Bissell M J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996; 76: 69–125, [INFOTRIEVE], [CSA]
- Tlsty T D, Hein P W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54–59, [INFOTRIEVE], [CSA], [CROSSREF]
- Bhowmick N A, Neilson E G, Moses H L. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332–337, [INFOTRIEVE], [CSA], [CROSSREF]
- Liotta L A, Kohn E C. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–379, [INFOTRIEVE], [CSA], [CROSSREF]
- Jung Y D, Ahmad S A, Liu W, Reinmuth N, Parikh A, Stoeltzing O, Fan F, Ellis L M. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 2002; 12: 105–112, [INFOTRIEVE], [CSA], [CROSSREF]
- Arribas J, Borroto A. Protein ectodomain shedding. Chem Rev 2002; 102: 4627–4638, [INFOTRIEVE], [CSA], [CROSSREF]
- Higashiyama S. Metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor and its pathophysiological roles. Protein Pept Lett 2004; 11: 443–450, [INFOTRIEVE], [CSA], [CROSSREF]
- Sahin U, Weskamp G, Kelly K, Zhou H M, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel C P. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769–779, [INFOTRIEVE], [CSA], [CROSSREF]
- Black R A. Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34: 1–5, [INFOTRIEVE], [CSA], [CROSSREF]
- Heiz M, Grunberg J, Schubiger P A, Novak-Hofer I. Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J Biol Chem 2004; 279: 31149–31156, [INFOTRIEVE], [CSA], [CROSSREF]
- Smalley D M, Ley K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 2005; 9: 255–266, [INFOTRIEVE], [CSA]
- Ohnishi H, Kobayashi H, Okazawa H, Ohe Y, Tomizawa K, Sato R, Matozaki T. Ectodomain shedding of SHPS-1 and its role in regulation of cell migration. J Biol Chem 2004; 279: 27878–27887, [INFOTRIEVE], [CSA], [CROSSREF]
- Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Stroher U, Klenk H D, Volchkov V. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 2004; 23: 2175–2184, [INFOTRIEVE], [CSA], [CROSSREF]
- Dello Sbarba P, Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol Chem 2002; 383: 69–83, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhao X J, Oliver P, Song K, Schurr J, Zhang Z, Kolls J K. Chronic ethanol enhances ectodomain shedding in T cells and monocytes. Alcohol Clin Exp Res 2004; 28: 1399–1407, [INFOTRIEVE], [CSA]
- Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 2005; 1751: 110–117, [INFOTRIEVE], [CSA]
- Werb Z, Yan Y. A cellular striptease act. Science 1998; 282: 1279–1280, [INFOTRIEVE], [CSA], [CROSSREF]
- Kiessling L L, Gordon E J. Transforming the cell surface through proteolysis. Chem Biol 1998; 5: R49–R62, [INFOTRIEVE], [CSA], [CROSSREF]
- Blobel C P. Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol 2000; 12: 606–612, [INFOTRIEVE], [CSA], [CROSSREF]
- Kheradmand F, Werb Z. Shedding light on sheddases: role in growth and development. Bioessays 2002; 24: 8–12, [INFOTRIEVE], [CSA], [CROSSREF]
- Rattner A, Chen J, Nathans J. Proteolytic shedding of the extracellular domain of photoreceptor cadherin. Implications for outer segment assembly. J Biol Chem 2004; 279: 42202–42210, [INFOTRIEVE], [CSA], [CROSSREF]
- Toki F, Nanba D, Matsuura N, Higashiyama S. Ectodomain shedding of membrane-anchored heparin-binding EGF like growth factor and subcellular localization of the C-terminal fragment in the cell cycle. J Cell Physiol 2005; 202: 839–848, [INFOTRIEVE], [CSA], [CROSSREF]
- Bridges L C, Bowditch R D. ADAM-integrin interactions: potential integrin regulated ectodomain shedding activity. Curr Pharm Des 2005; 11: 837–847, [INFOTRIEVE], [CSA], [CROSSREF]
- Huovila A P, Turner A J, Pelto-Huikko M, Karkkainen I, Ortiz R M. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30: 413–422, [INFOTRIEVE], [CSA], [CROSSREF]
- Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005; 102: 9182–9187, [INFOTRIEVE], [CSA], [CROSSREF]
- Graves L E, Ariztia E V, Navari J R, Matzel H J, Stack M S, Fishman D A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004; 64: 7045–7049, [INFOTRIEVE], [CSA], [CROSSREF]
- Fishman D A, Liu Y, Ellerbroek S M, Stack M S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001; 61: 3194–3199, [INFOTRIEVE], [CSA]
- Bayless K J, Davis G E. Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. Biochem Biophys Res Commun 2003; 312: 903–913, [INFOTRIEVE], [CSA], [CROSSREF]
- So J, Navari J, Wang F Q, Fishman D A. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 2004; 95: 314–322, [INFOTRIEVE], [CSA], [CROSSREF]
- So J, Wang F Q, Navari J, Schreher J, Fishman D A. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005; 97: 870–878, [INFOTRIEVE], [CSA]
- Shekhar M P, Werdell J, Santner S J, Pauley R J, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001; 61: 1320–1326, [INFOTRIEVE], [CSA]
- Camps J L, Chang S M, Hsu T C, Freeman M R, Hong S J, Zhau H E, von Eschenbach A C, Chung L W. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 1990; 87: 75–79, [INFOTRIEVE], [CSA], [CROSSREF]
- Olumi A F, Grossfeld G D, Hayward S W, Carroll P R, Tlsty T D, Cunha G R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002–5011, [INFOTRIEVE], [CSA]
- Atula S, Grenman R, Syrjanen S. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp Cell Res 1997; 235: 180–187, [INFOTRIEVE], [CSA], [CROSSREF]
- Parrott J A, Nilsson E, Mosher R, Magrane G, Albertson D, Pinkel D, Gray J W, Skinner M K. Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells. Mol Cell Endocrinol 2001; 175: 29–39, [INFOTRIEVE], [CSA], [CROSSREF]
- Chung L W, Baseman A, Assikis V, Zhau H E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005; 173: 10–20, [INFOTRIEVE], [CSA]
- De Raeve H R, Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 2005; 20: 1227–1250, [INFOTRIEVE], [CSA]
- Barcellos-Hoff M H, Ravani S A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000; 60: 1254–1260, [INFOTRIEVE], [CSA]
- Ohuchida K, Mizumoto K, Murakami M, Qian L W, Sato N, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004; 64: 3215–3222, [INFOTRIEVE], [CSA], [CROSSREF]
- Tsai K K, Chuang E Y, Little J B, Yuan Z M. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res 2005; 65: 6734–6744, [INFOTRIEVE], [CSA], [CROSSREF]
- Krtolica A, Parrinello S, Lockett S, Desprez P Y, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001; 98: 12072–12077, [INFOTRIEVE], [CSA], [CROSSREF]
- Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, Christensen A, Andresen S, Kruse C, Hansen T, Ambartsumian N, Lukanidin E, Grigorian M. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem 2004; 279: 24498–24504, [INFOTRIEVE], [CSA], [CROSSREF]
- Grum-Schwensen B, Klingelhofer J, Berg C H, El-Naaman C, Grigorian M, Lukanidin E, Ambartsumian N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005; 65: 3772–3780, [INFOTRIEVE], [CSA], [CROSSREF]
- Moinfar F, Man Y G, Arnould L, Bratthauer G L, Ratschek M, Tavassoli F A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000; 60: 2562–2566, [INFOTRIEVE], [CSA]
- Moinfar F, Kremser M L, Man Y G, Zatloukal K, Tavassoli F A, Denk H. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues. Gynecol Oncol 2004; 95: 662–671, [INFOTRIEVE], [CSA], [CROSSREF]
- Man Y G, Magrane G G, Lininger R A, Shen T, Kuhls E, Bratthauer G L. Morphologically similar epithelial and stromal cells in primary bilateral breast tumors display different genetic profiles: implications for treatment. Appl Immunohistochem Mol Morphol 2004; 12: 305–314, [INFOTRIEVE], [CSA]
- Bissell M J, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46–54, [INFOTRIEVE], [CSA]
- Dunn I F, Heese O, Black P M. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000; 50: 121–137, [INFOTRIEVE], [CSA]
- Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709–724, [INFOTRIEVE], [CSA], [CROSSREF]
- Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179–186, [INFOTRIEVE], [CSA], [CROSSREF]
- Thomson A A, Foster B A, Cunha G R. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 1997; 124: 2431–2439, [INFOTRIEVE], [CSA]
- Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan W L. Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 1992; 6: 2123–2128, [INFOTRIEVE], [CSA], [CROSSREF]
- Leung H Y, Dickson C, Robson C N, Neal D E. Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996; 12: 1833–1835, [INFOTRIEVE], [CSA]
- Lu W, Luo Y, Kan M, McKeehan W L. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999; 274: 12827–12834, [INFOTRIEVE], [CSA], [CROSSREF]
- Thomson A A, Cunha G R. Prostatic growth and development are regulated by FGF10. Development 1999; 126: 3693–3701, [INFOTRIEVE], [CSA]
- Song Z, Powell W C, Kasahara N, van Bokhoven A, Miller G J, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000; 60: 6730–6736, [INFOTRIEVE], [CSA]
- Gnanapragasam V J, Robinson M C, Marsh C, Robson C N, Hamdy F C, Leung H Y. FGF8 isoform b expression in human prostate cancer. Br J Cancer 2003; 88: 1432–1438, [INFOTRIEVE], [CSA], [CROSSREF]
- Heer R, Douglas D, Mathers M E, Robson C N, Leung H Y. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004; 204: 578–586, [INFOTRIEVE], [CSA], [CROSSREF]
- Arbeit J M, Olson D C, Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996; 13: 1847–1857, [INFOTRIEVE], [CSA]
- Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66: 1095–1104, [INFOTRIEVE], [CSA], [CROSSREF]
- Okada-Ban M, Moens G, Thiery J P, Jouanneau J. Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene 1999; 18: 6719–6724, [INFOTRIEVE], [CSA], [CROSSREF]
- Yasumoto H, Matsubara A, Mutaguchi K, Usui T, McKeehan W L. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate 2004; 61: 236–242, [INFOTRIEVE], [CSA], [CROSSREF]
- Nakamura T, Matsumoto K, Kiritoshi A, Tano Y. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305–3313, [INFOTRIEVE], [CSA]
- Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915–925, [INFOTRIEVE], [CSA], [CROSSREF]
- Higashio K, Shima N, Goto M, Itagaki Y, Nagao M, Yasuda H, Morinaga T. Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem Biophys Res Commun 1990; 170: 397–404, [INFOTRIEVE], [CSA], [CROSSREF]
- Shima N, Itagaki Y, Nagao M, Yasuda H, Morinaga T, Higashio K. A fibroblast-derived tumor cytotoxic factor/F-TCF (hepatocyte growth factor/HGF) has multiple functions in vitro. Cell Biol Int Rep 1991; 15: 397–408, [INFOTRIEVE], [CSA], [CROSSREF]
- Shiota G, Rhoads D B, Wang T C, Nakamura T, Schmidt E V. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992; 89: 373–377, [INFOTRIEVE], [CSA], [CROSSREF]
- Comoglio P M, Boccaccio C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1996; 1: 347–354, [INFOTRIEVE], [CSA], [CROSSREF]
- Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54: 1630–1633, [INFOTRIEVE], [CSA]
- Yao Y, Jin L, Fuchs A, Joseph A, Hastings H M, Goldberg I D, Rosen E M. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol 1996; 149: 1707–1717, [INFOTRIEVE], [CSA]
- Siegfried J M, Weissfeld L A, Singh-Kaw P, Weyant R J, Testa J R, Landreneau R J. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 433–439, [INFOTRIEVE], [CSA]
- Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A, Toi M. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 1997; 75: 673–677, [INFOTRIEVE], [CSA]
- Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997; 25: 619–623, [INFOTRIEVE], [CSA], [CROSSREF]
- Naughton M, Picus J, Zhu X, Catalona W J, Vollmer R T, Humphrey P A. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001; 165: 1325–1328, [INFOTRIEVE], [CSA], [CROSSREF]
- Ayhan A, Ertunc D, Tok E C. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005; 15: 618–623, [INFOTRIEVE], [CSA], [CROSSREF]
- Ren Y, Cao B, Law S, Xie Y, Lee P Y, Cheung L, Chen Y, Huang X, Chan H M, Zhao P, Luk J, Vande Woude G, Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005; 11: 6190–6197, [INFOTRIEVE], [CSA], [CROSSREF]
- Elliott R L, Blobe G C. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005; 23: 2078–2093, [INFOTRIEVE], [CSA], [CROSSREF]
- Bhowmick N A, Chytil A, Plieth D, Gorska A E, Dumont N, Shappell S, Washington M K, Neilson E G, Moses H L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848–851, [INFOTRIEVE], [CSA], [CROSSREF]
- Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339–347, [INFOTRIEVE], [CSA]
- Bergers G, Benjamin L E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401–410, [INFOTRIEVE], [CSA], [CROSSREF]
- Milkiewicz M, Ispanovic E, Doyle J L, Haas T L. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006; 38: 333–357, [INFOTRIEVE], [CSA], [CROSSREF]
- Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3)S4–S10, [CSA], [CROSSREF]
- Berse B, Brown L F, Van de Water L, Dvorak H F, Senger D R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211–220, [INFOTRIEVE], [CSA]
- Thomas K A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271: 603–606, [INFOTRIEVE], [CSA]
- Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(Suppl 1)S2–S10, [CSA], [CROSSREF]
- Levy A P, Levy N S, Wegner S, Goldberg M A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333–13340, [INFOTRIEVE], [CSA], [CROSSREF]
- Shi Q, Abbruzzese J L, Huang S, Fidler I J, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999; 5: 3711–3721, [INFOTRIEVE], [CSA]
- Xu L, Xie K, Mukaida N, Matsushima K, Fidler I J. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999; 59: 5822–5829, [INFOTRIEVE], [CSA]
- Dewhirst M W, Richardson R, Cardenas-Navia I, Cao Y. The relationship between the tumor physiologic microenvironment and angiogenesis. Hematol Oncol Clin North Am 2004; 18: 973–990, [INFOTRIEVE], [CSA], [CROSSREF]
- Fidler I J. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 2001; 10: 257–269, [INFOTRIEVE], [CSA]
- Fidler I J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst 2001; 93: 1040–1041, [INFOTRIEVE], [CSA], [CROSSREF]
- Singh R K, Bucana C D, Gutman M, Fan D, Wilson M R, Fidler I J. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 1994; 145: 365–374, [INFOTRIEVE], [CSA]
- Pages G, Milanini J, Richard D E, Berra E, Gothie E, Vinals F, Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann NY Acad Sci 2000; 902: 187–200, [INFOTRIEVE], [CSA]
- Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024–1028, [INFOTRIEVE], [CSA], [CROSSREF]
- Harmey J H, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002; 24: 280–283, [INFOTRIEVE], [CSA], [CROSSREF]
- Mandriota S J, Seghezzi G, Vassalli J D, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper M S. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270: 9709–9716, [INFOTRIEVE], [CSA], [CROSSREF]
- Pepper M S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104–1117, [INFOTRIEVE], [CSA]
- Bajou K, Maillard C, Jost M, Lijnen R H, Gils A, Declerck P, Carmeliet P, Foidart J M, Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004; 23: 6986–6990, [INFOTRIEVE], [CSA]
- Prager G W, Breuss J M, Steurer S, Olcaydu D, Mihaly J, Brunner P M, Stockinger H, Binder B R. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004; 94: 1562–1570, [INFOTRIEVE], [CSA]
- Kalebic T, Garbisa S, Glaser B, Liotta L A. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983; 221: 281–283, [INFOTRIEVE], [CSA], [CROSSREF]
- Lynch C C, Matrisian L M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561–573, [INFOTRIEVE], [CSA], [CROSSREF]
- Haas T L. Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol 2005; 83: 1–7, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang F Q, So J, Reierstad S, Fishman D A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006; 118: 879–888, [INFOTRIEVE], [CSA], [CROSSREF]
- Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224–5229, [INFOTRIEVE], [CSA]
- Abu-Jawdeh G M, Faix J D, Niloff J, Tognazzi K, Manseau E, Dvorak H F, Brown L F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74: 1105–1115, [INFOTRIEVE], [CSA]
- Boocock C A, Charnock-Jones D S, Sharkey A M, McLaren J, Barker P J, Wright K A, Twentyman P R, Smith S K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–516, [INFOTRIEVE], [CSA]
- Auersperg N, Wong A S, Choi K C, Kang S K, Leung P C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255–288, [INFOTRIEVE], [CSA], [CROSSREF]
- Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 2002; 84: 47–52, [INFOTRIEVE], [CSA], [CROSSREF]
- Gadducci A, Viacava P, Cosio S, Cecchetti D, Fanelli G, Fanucchi A, Teti G, Genazzani A R. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003; 23: 3001–3008, [INFOTRIEVE], [CSA]
- Wong C, Wellman T L, Lounsbury K M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003; 91: 513–517, [INFOTRIEVE], [CSA], [CROSSREF]
- Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 1997; 17: 621–624, [INFOTRIEVE], [CSA]
- Mesiano S, Ferrara N, Jaffe R B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249–1256, [INFOTRIEVE], [CSA]
- Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997; 76: 1221–1227, [INFOTRIEVE], [CSA]
- Hartenbach E M, Olson T A, Goswitz J J, Mohanraj D, Twiggs L B, Carson L F, Ramakrishnan S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997; 121: 169–175, [INFOTRIEVE], [CSA], [CROSSREF]
- Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998; 92: 360–363, [INFOTRIEVE], [CSA], [CROSSREF]
- Oehler M K, Caffier H. Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Res 1999; 19: 2519–2522, [INFOTRIEVE], [CSA]
- Kaplan R N, Riba R D, Zacharoulis S, Bramley A H, Vincent L, Costa C, MacDonald D D, Jin D K, Shido K, Kerns S A, Zhu Z, Hicklin D, Wu Y, Port J L, Altorki N, Port E R, Ruggero D, Shmelkov S V, Jensen K K, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820–827, [INFOTRIEVE], [CSA], [CROSSREF]
- Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–336, [INFOTRIEVE], [CSA], [CROSSREF]
- Mignatti P, Rifkin D B. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161–195, [INFOTRIEVE], [CSA]
- Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755: 37–69, [INFOTRIEVE], [CSA]
- Hood J D, Cheresh D A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2: 91–100, [INFOTRIEVE], [CSA], [CROSSREF]
- Kuphal S, Bauer R, Bosserhoff A K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005; 24: 195–222, [INFOTRIEVE], [CSA], [CROSSREF]
- Danen E H. Integrins: regulators of tissue function and cancer progression. Curr Pharm Des 2005; 11: 881–891, [INFOTRIEVE], [CSA], [CROSSREF]
- Handsley M M, Edwards D R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849–860, [INFOTRIEVE], [CSA], [CROSSREF]
- Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048–1051, [INFOTRIEVE], [CSA]
- Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler I J. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134–1142, [INFOTRIEVE], [CSA]
- Silletti S, Kessler T, Goldberg J, Boger D L, Cheresh D A. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001; 98: 119–124, [INFOTRIEVE], [CSA], [CROSSREF]
- Nisato R E, Hosseini G, Sirrenberg C, Butler G S, Crabbe T, Docherty A J, Wiesner M, Murphy G, Overall C M, Goodman S L, Pepper M S. Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res 2005; 65: 9377–9387, [INFOTRIEVE], [CSA], [CROSSREF]
- Deryugina E I, Soroceanu L, Strongin A Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002; 62: 580–588, [INFOTRIEVE], [CSA]
- Sounni N E, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson E W, Foidart J M, Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002; 16: 555–564, [INFOTRIEVE], [CSA], [CROSSREF]
- Tang Y, Nakada M T, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65: 3193–3199, [INFOTRIEVE], [CSA]
- Bergers G, Brekken R, McMahon G, Vu T H, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737–744, [INFOTRIEVE], [CSA], [CROSSREF]
- Chantrain C F, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky D R, Werb Z, Coussens L M, DeClerck Y A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64: 1675–1686, [INFOTRIEVE], [CSA], [CROSSREF]
- Jodele S, Chantrain C F, Blavier L, Lutzko C, Crooks G M, Shimada H, Coussens L M, Declerck Y A. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res 2005; 65: 3200–3208, [INFOTRIEVE], [CSA]
- Hangai M, Kitaya N, Xu J, Chan C K, Kim J J, Werb Z, Ryan S J, Brooks P C. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002; 161: 1429–1437, [INFOTRIEVE], [CSA]
- Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001; 82: 291–298, [INFOTRIEVE], [CSA], [CROSSREF]
- Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001; 7: 2396–2404, [INFOTRIEVE], [CSA]
- Zhao Z S, Zhou J L, Yao G Y, Ru G Q, Ma J, Ruan J. Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol 2005; 11: 3227–3233, [INFOTRIEVE], [CSA]
- Cornelius L A, Nehring L C, Harding E, Bolanowski M, Welgus H G, Kobayashi D K, Pierce R A, Shapiro S D. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998; 161: 6845–6852, [INFOTRIEVE], [CSA]
- Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 2003; 100: 4766–4771, [INFOTRIEVE], [CSA], [CROSSREF]
- Dutour A, Rigaud M. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Anticancer Res 2005; 25: 3799–3807, [INFOTRIEVE], [CSA]
- Pradeep C R, Sunila E S, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005; 4: 315–321, [INFOTRIEVE], [CSA], [CROSSREF]
- Aznavoorian S, Murphy A N, Stetler-Stevenson W G, Liotta L A. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71: 1368–1383, [INFOTRIEVE], [CSA], [CROSSREF]
- Yoneda J, Kuniyasu H, Crispens M A, Price J E, Bucana C D, Fidler I J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447–454, [INFOTRIEVE], [CSA], [CROSSREF]
- Orre M, Rogers P A. Macrophages and microvessel density in tumors of the ovary. Gynecol Oncol 1999; 73: 47–50, [INFOTRIEVE], [CSA], [CROSSREF]
- Coussens L M, Tinkle C L, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481–490, [INFOTRIEVE], [CSA], [CROSSREF]
- Huang L W, Garrett A P, Bell D A, Welch W R, Berkowitz R S, Mok S C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000; 77: 369–376, [INFOTRIEVE], [CSA], [CROSSREF]
- Brooks P C, Stromblad S, Sanders L C, von Schalscha T L, Aimes R T, Stetler-Stevenson W G, Quigley J P, Cheresh D A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683–693, [INFOTRIEVE], [CSA], [CROSSREF]
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161–174, [INFOTRIEVE], [CSA]
- Monsky W L, Kelly T, Lin C Y, Yeh Y, Stetler-Stevenson W G, Mueller S C, Chen W T. Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res 1993; 53: 3159–3164, [INFOTRIEVE], [CSA]
- Ellerbroek S M, Fishman D A, Kearns A S, Bafetti L M, Stack M S. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999; 59: 1635–1641, [INFOTRIEVE], [CSA]
- Stetler-Stevenson W G, Yu A E. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11: 143–152, [INFOTRIEVE], [CSA], [CROSSREF]
- Bourguignon L Y, Gunja-Smith Z, Iida N, Zhu H B, Young L J, Muller W J, Cardiff R D. CD44v(3,8–10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176: 206–215, [INFOTRIEVE], [CSA], [CROSSREF]
- Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35–48, [INFOTRIEVE], [CSA]
- Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001; 153: 893–904, [INFOTRIEVE], [CSA], [CROSSREF]
- Davies G, Jiang W G, Mason M D. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001; 7: 3289–3297, [INFOTRIEVE], [CSA]
- Noe V, Fingleton B, Jacobs K, Crawford H C, Vermeulen S, Steelant W, Bruyneel E, Matrisian L M, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114: 111–118, [INFOTRIEVE], [CSA]
- Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003; 22: 8662–8670, [INFOTRIEVE], [CSA], [CROSSREF]
- Roark E F, Paradies N E, Lagunowich L A, Grunwald G B. Evidence for endogenous proteases, mRNA level and insulin as multiple mechanisms of N-cadherin down-regulation during retinal development. Development 1992; 114: 973–984, [INFOTRIEVE], [CSA]
- Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003; 278: 40764–40770, [INFOTRIEVE], [CSA], [CROSSREF]
- Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005; 96: 212–217, [INFOTRIEVE], [CSA], [CROSSREF]
- Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194: 1–11, [INFOTRIEVE], [CSA], [CROSSREF]
- Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, Seiki M, Sato H. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 2003; 22: 4617–4626, [INFOTRIEVE], [CSA], [CROSSREF]
- Schenk S, Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol 2003; 13: 366–375, [INFOTRIEVE], [CSA], [CROSSREF]
- Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W G, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 277: 225–228, [INFOTRIEVE], [CSA], [CROSSREF]
- Demeter A, Sziller I, Csapo Z, Olah J, Keszler G, Jeney A, Papp Z, Staub M. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res 2005; 25: 2885–2889, [INFOTRIEVE], [CSA]
- Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer 2001; 84: 1488–1496, [INFOTRIEVE], [CSA], [CROSSREF]
- Zeng Z S, Huang Y, Cohen A M, Guillem J G. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133–3140, [INFOTRIEVE], [CSA]
- Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997; 88: 72–81, [INFOTRIEVE], [CSA]
- Kulbe H, Hagemann T, Szlosarek P W, Balkwill F R, Wilson J L. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005; 65: 10355–10362, [INFOTRIEVE], [CSA], [CROSSREF]
- Hagemann T, Robinson S C, Schulz M, Trumper L, Balkwill F R, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004; 25: 1543–1549, [INFOTRIEVE], [CSA], [CROSSREF]
- Szlosarek P W, Balkwill F R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4: 565–573, [INFOTRIEVE], [CSA], [CROSSREF]
- Kumar S, Kishimoto H, Chua H L, Badve S, Miller K D, Bigsby R M, Nakshatri H. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol 2003; 163: 2531–2541, [INFOTRIEVE], [CSA]
- Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002; 12: 113–120, [INFOTRIEVE], [CSA], [CROSSREF]
- Malik S T, Griffin D B, Fiers W, Balkwill F R. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int J Cancer 1989; 44: 918–925, [INFOTRIEVE], [CSA]
- Moore R J, Owens D M, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828–831, [INFOTRIEVE], [CSA], [CROSSREF]
- Kashii Y, Giorda R, Herberman R B, Whiteside T L, Vujanovic N L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999; 163: 5358–5366, [INFOTRIEVE], [CSA]
- Idriss H T, Naismith J H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50: 184–195, [INFOTRIEVE], [CSA], [CROSSREF]
- Yu J L, Rak J W. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003; 5: 83–88, [INFOTRIEVE], [CSA], [CROSSREF]
- Ribatti D, Crivellato E, Roccaro A M, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004; 34: 1660–1664, [INFOTRIEVE], [CSA], [CROSSREF]
- Yuan A, Chen J J, Yao P L, Yang P C. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005; 10: 853–865, [INFOTRIEVE], [CSA]
- Lu Y, Wahl L M. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol 2005; 78: 259–265, [INFOTRIEVE], [CSA], [CROSSREF]
- Stuelten C H, Byfield S D, Arany P R, Karpova T S, Stetler-Stevenson W G, Roberts A B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005; 118: 2143–2153, [INFOTRIEVE], [CSA], [CROSSREF]
- Scotton C J, Wilson J L, Scott K, Stamp G, Wilbanks G D, Fricker S, Bridger G, Balkwill F R. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930–5938, [INFOTRIEVE], [CSA]
- Negus R P, Stamp G W, Relf M G, Burke F, Malik S T, Bernasconi S, Allavena P, Sozzani S, Mantovani A, Balkwill F R. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995; 95: 2391–2396, [INFOTRIEVE], [CSA]
- Negus R P, Stamp G W, Hadley J, Balkwill F R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997; 150: 1723–1734, [INFOTRIEVE], [CSA]
- Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer 2001; 85: 891–897, [INFOTRIEVE], [CSA], [CROSSREF]
- Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002; 8: 1108–1114, [INFOTRIEVE], [CSA]
- Bottazzi B, Ghezzi P, Taraboletti G, Salmona M, Colombo N, Bonazzi C, Mangioni C, Mantovani A. Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues. Int J Cancer 1985; 36: 167–173, [INFOTRIEVE], [CSA]
- Leonard E J, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990; 11: 97–101, [INFOTRIEVE], [CSA], [CROSSREF]
- Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282–3289, [INFOTRIEVE], [CSA]
- Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983; 220: 210–212, [INFOTRIEVE], [CSA], [CROSSREF]
- Belperio J A, Keane M P, Arenberg D A, Addison C L, Ehlert J E, Burdick M D, Strieter R M. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1–8, [INFOTRIEVE], [CSA]
- Rempel S A, Dudas S, Ge S, Gutierrez J A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000; 6: 102–111, [INFOTRIEVE], [CSA]
- Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz I P, Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747–4757, [INFOTRIEVE], [CSA]
- Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan M E, McClanahan T, Murphy E, Yuan W, Wagner S N, Barrera J L, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–56, [INFOTRIEVE], [CSA], [CROSSREF]
- Murphy P M. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001; 345: 833–835, [INFOTRIEVE], [CSA], [CROSSREF]
- Scotton C J, Wilson J L, Milliken D, Stamp G, Balkwill F R. Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res 2001; 61: 4961–4965, [INFOTRIEVE], [CSA]
- Strieter R M. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001; 2: 285–286, [INFOTRIEVE], [CSA], [CROSSREF]
- Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005; 308: 241–253, [INFOTRIEVE], [CSA]
- Burger J A, Kipps T J. CXCR4: A key receptor in the cross talk between tumor cells and their microenvironment. Blood 2006; 107: 1761–1767, [INFOTRIEVE], [CSA]
- Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett N R, Crystal R G, Besmer P, Lyden D, Moore M A, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625–637, [INFOTRIEVE], [CSA], [CROSSREF]
- Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel R E, Jiang W G. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005; 7: R402–R410, [INFOTRIEVE], [CSA], [CROSSREF]
- Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, Oy E, Aktas E, Bilgic S, Kiran B, Deniz G, Price J E. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005; 22: 39–46, [INFOTRIEVE], [CSA], [CROSSREF]
- Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550: 79–83, [INFOTRIEVE], [CSA], [CROSSREF]
- Takenaga M, Tamamura H, Hiramatsu K, Nakamura N, Yamaguchi Y, Kitagawa A, Kawai S, Nakashima H, Fujii N, Igarashi R. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004; 320: 226–232, [INFOTRIEVE], [CSA], [CROSSREF]
- Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2005; 9: 1267–1282, [INFOTRIEVE], [CSA], [CROSSREF]
- Baselga J, Mendelsohn J, Kim Y M, Pandiella A. Autocrine regulation of membrane transforming growth factor-alpha cleavage. J Biol Chem 1996; 271: 3279–3284, [INFOTRIEVE], [CSA], [CROSSREF]
- Jones S A, Novick D, Horiuchi S, Yamamoto N, Szalai A J, Fuller G M. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189: 599–604, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee R K, Wurtman R J. Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann NY Acad Sci 2000; 920: 261–268, [INFOTRIEVE], [CSA]
- Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64: 5720–5727, [INFOTRIEVE], [CSA], [CROSSREF]
- Dong J, Opresko L K, Dempsey P J, Lauffenburger D A, Coffey R J, Wiley H S. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci USA 1999; 96: 6235–6240, [INFOTRIEVE], [CSA], [CROSSREF]
- Shi W, Fan H, Shum L, Derynck R. The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. J Cell Biol 2000; 148: 591–602, [INFOTRIEVE], [CSA], [CROSSREF]
- Yang H, Jiang D, Li W, Liang J, Gentry L E, Brattain M G. Defective cleavage of membrane bound TGFalpha leads to enhanced activation of the EGF receptor in malignant cells. Oncogene 2000; 19: 1901–1914, [INFOTRIEVE], [CSA], [CROSSREF]
- Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884–888, [INFOTRIEVE], [CSA]
- Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E. The stress-and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate-and lysophosphatidic acid-induced signaling cascades. J Biol Chem 2003; 278: 17255–17262, [INFOTRIEVE], [CSA], [CROSSREF]
- Codony-Servat J, Albanell J, Lopez-Talavera J C, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999; 59: 1196–1201, [INFOTRIEVE], [CSA]
- Yabkowitz R, Meyer S, Black T, Elliott G, Merewether L A, Yamane H K. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999; 93: 1969–1979, [INFOTRIEVE], [CSA]
- Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer J S, Basak A, Lazure C, Cromlish J A, Sisodia S, Checler F, Chretien M, Seidah N G. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 2001; 276: 10879–10887, [INFOTRIEVE], [CSA], [CROSSREF]
- Li G, Percontino L, Sun Q, Qazi A S, Frederikse P H. Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens. Mol Vis 2003; 9: 179–183, [INFOTRIEVE], [CSA]
- Gasbarri A, Del Prete F, Girnita L, Martegani M P, Natali P G, Bartolazzi A. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Res 2003; 13: 325–337, [INFOTRIEVE], [CSA], [CROSSREF]
- Fitzgerald M L, Wang Z, Park P W, Murphy G, Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000; 148: 811–824, [INFOTRIEVE], [CSA], [CROSSREF]
- Feehan C, Darlak K, Kahn J, Walcheck B, Spatola A F, Kishimoto T K. Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter. J Biol Chem 1996; 271: 7019–7024, [INFOTRIEVE], [CSA], [CROSSREF]
- Fors B P, Goodarzi K, von Andrian U H. L-selectin shedding is independent of its subsurface structures and topographic distribution. J Immunol 2001; 167: 3642–3651, [INFOTRIEVE], [CSA]
- Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005; 24: 742–752, [INFOTRIEVE], [CSA], [CROSSREF]
- Beer S, Oleszewski M, Gutwein P, Geiger C, Altevogt P. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci 1999; 112: 2667–2675, [INFOTRIEVE], [CSA]
- Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000; 275: 15490–15497, [INFOTRIEVE], [CSA], [CROSSREF]
- Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001; 155: 661–673, [INFOTRIEVE], [CSA], [CROSSREF]
- Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M, Altevogt D P. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J 2003; 17: 292–294, [INFOTRIEVE], [CSA]
- Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon T P, Marme A, Phong M C, Linderkamp O, Skorokhod A, Altevogt P. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 2005; 11: 2492–2501, [INFOTRIEVE], [CSA], [CROSSREF]
- Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163–176, [INFOTRIEVE], [CSA]
- Mitsiades N, Yu W H, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577–581, [INFOTRIEVE], [CSA]
- McQuibban G A, Gong J H, Tam E M, McCulloch C A, Clark-Lewis I, Overall C M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202–1206, [INFOTRIEVE], [CSA], [CROSSREF]
- Taylor D D, Black P H. Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol 1986; 3: 33–57, [CSA]
- Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli M L. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 1994; 26: 173–180, [INFOTRIEVE], [CSA]
- Cassara D, Ginestra A, Dolo V, Miele M, Caruso G, Lucania G, Vittorelli M L. Modulation of vesicle shedding in 8701 BC human breast carcinoma cells. J Submicrosc Cytol Pathol 1998; 30: 45–53, [INFOTRIEVE], [CSA]
- Ginestra A, La Placa M D, Saladino F, Cassara D, Nagase H, Vittorelli M L. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 1998; 18: 3433–3437, [INFOTRIEVE], [CSA]
- Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli M L, Canevari S, Pavan A. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 1999; 17: 131–140, [INFOTRIEVE], [CSA], [CROSSREF]
- Angelucci A, D'Ascenzo S, Festuccia C, Gravina G L, Bologna M, Dolo V, Pavan A. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 2000; 18: 163–170, [INFOTRIEVE], [CSA], [CROSSREF]
- Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002; 160: 673–680, [INFOTRIEVE], [CSA]
- Dolo V, Adobati E, Canevari S, Picone M A, Vittorelli M L. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 1995; 13: 277–286, [INFOTRIEVE], [CSA], [CROSSREF]
- Taylor D D, Gercel-Taylor C, Lyons K S, Stanson J, Whiteside T L. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9: 5113–5119, [INFOTRIEVE], [CSA]
- Abrahams V M, Straszewski S L, Kamsteeg M, Hanczaruk B, Schwartz P E, Rutherford T J, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573–5581, [INFOTRIEVE], [CSA]
- Meng Y, Kang S, Fishman D A. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer Immunol Immunother 2005; 54: 807–814, [INFOTRIEVE], [CSA], [CROSSREF]
- Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for “old” ligands. J Cell Biochem 2004; 92: 923–936, [INFOTRIEVE], [CSA], [CROSSREF]
- Chun J, Goetzl E J, Hla T, Igarashi Y, Lynch K R, Moolenaar W, Pyne S, Tigyi G. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002; 54: 265–269, [INFOTRIEVE], [CSA], [CROSSREF]
- Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73: 321–354, [INFOTRIEVE], [CSA], [CROSSREF]
- Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25600–25606, [INFOTRIEVE], [CSA], [CROSSREF]
- Fischer D J, Nusser N, Virag T, Yokoyama K, Wang D, Baker D L, Bautista D, Parrill A L, Tigyi G. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 2001; 60: 776–784, [INFOTRIEVE], [CSA]
- Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im D S, Nochi H, Tamoto K, Tomura H, Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994–1005, [INFOTRIEVE], [CSA], [CROSSREF]
- Anliker B, Chun J. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 2004; 15: 457–465, [INFOTRIEVE], [CSA]
- Moolenaar W H, van Meeteren L A, Giepmans B N. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004; 26: 870–881, [INFOTRIEVE], [CSA]
- Gududuru V, Zeng K, Tsukahara R, Makarova N, Fujiwara Y, Pigg K R, Baker D L, Tigyi G, Miller D D. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. Bioorg Med Chem Lett 2006; 16: 451–456, [INFOTRIEVE], [CSA], [CROSSREF]
- Meng Y, Kang S, So J, Reierstad S, Fishman D A. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol 2005; 96: 462–469, [INFOTRIEVE], [CSA], [CROSSREF]
- Meng Y, Kang S, Fishman D A. Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer. FEBS Lett 2005; 579: 1311–1319, [INFOTRIEVE], [CSA], [CROSSREF]
- Xu Y, Shen Z, Wiper D W, Wu M, Morton R E, Elson P, Kennedy A W, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719–723, [INFOTRIEVE], [CSA], [CROSSREF]
- Sutphen R, Xu Y, Wilbanks G D, Fiorica J, Grendys E C, Jr., LaPolla J P, Arango H, Hoffman M S, Martino M, Wakeley K, Griffin D, Blanco R W, Cantor A B, Xiao Y J, Krischer J P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1185–1191, [INFOTRIEVE], [CSA]
- Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills G B, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227–233, [INFOTRIEVE], [CSA], [CROSSREF]
- Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002; 277: 39436–39442, [INFOTRIEVE], [CSA], [CROSSREF]
- van Meeteren L A, Ruurs P, Christodoulou E, Goding J W, Takakusa H, Kikuchi K, Perrakis A, Nagano T, Moolenaar W H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 2005; 280: 21155–21161, [INFOTRIEVE], [CSA], [CROSSREF]
- Clair T, Koh E, Ptaszynska M, Bandle R W, Liotta L A, Schiffmann E, Stracke M L. L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 2005; 4: 5, [INFOTRIEVE], [CSA], [CROSSREF]
- Durgam G G, Virag T, Walker M D, Tsukahara R, Yasuda S, Liliom K, van Meeteren L A, Moolenaar W H, Wilke N, Siess W, Tigyi G, Miller D D. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 2005; 48: 4919–4930, [INFOTRIEVE], [CSA], [CROSSREF]